Results 21 to 30 of about 15,139,370 (299)
Immune‐related Adverse Events in Cancer Patients [PDF]
AbstractThe U.S. Food and Drug Administration has approved immune checkpoint inhibitors and chimeric antigen receptor T cells (CAR‐T cells) as immunotherapy strategies for cancer. These therapies cause a wide variety of adverse events, which mimic other disease states and may emerge months after completion of treatment.
Daniel J, Pallin +5 more
openaire +2 more sources
Immune-related adverse events.
Immune-related adverse events.
Yuji Miyoshi (3172629) +5 more
core +1 more source
BackgroundImmune checkpoint inhibitors targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed death-1 receptor (PD-1), and programmed death-1 receptor and its ligand (PD-L1) increased the survival of patients affected by metastatic ...
Maria Anna Siciliano +9 more
doaj +1 more source
Vasospastic Angina: An Immune-related Adverse Event
A 54-year-old Japanese woman was admitted to our ward because of recurrent chest pain at rest for 2 months. She had been treated with nivolumab, an immune checkpoint inhibitor for inoperable advanced hypopharyngeal cancer for 21 months. She had no chest pain after cessation of nivolumab treatment.
Kumamoto, Taku +6 more
openaire +3 more sources
Objectives: To report real-world data of a cohort of patients treated with immune-checkpoint inhibitors in Brazil, with focus in immune-related adverse events.
Allan Andersson Lima Pereira +9 more
core +1 more source
Immune-related adverse events included in the online application.
Immune-related adverse events included in the online application.
Ryuji Matsumoto (1992658) +8 more
core +1 more source
Details of immune-related adverse events.
Details of immune-related adverse events.
Yuji Miyoshi (3172629) +5 more
core +1 more source
Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
PurposeTo investigate the incidence of immune-related adverse events (irAEs) of immune checkpoint inhibitor (ICI) therapy and to report the clinical features, management, and outcomes of ophthalmic irAEs.MethodsWe retrospectively reviewed the medical ...
Linyang Gan +3 more
doaj +1 more source
Treatment with immune checkpoint inhibitors (ICIs) has improved the prognosis of melanoma patients. However, ICIs can cause an overactivation of the immune system followed by diverse immunological side effects known as immune-related adverse events (irAE)
Alisa Lepper +6 more
doaj +1 more source
Immunotherapy (IT) in the form of monoclonal antibodies targeting coreceptors involved in the modulation of the immune synapse represents a standard of care for patients with distinct malignancies.
Andréia Cristina de Melo +22 more
core +1 more source

